Publications by authors named "Terje Soerdal"
Study Question: How does a gonadotrophin-releasing hormone (GnRH) agonist versus a GnRH antagonist protocol affect ovarian response when using an individualized fixed daily dose of follitropin delta for ovarian stimulation?
Summary Answer: The BEYOND trial data demonstrate thatindividualized fixed-dose follitropin delta is effective when used in a GnRH agonist protocol, compared with a GnRH antagonist protocol, in women with anti-Müllerian hormone (AMH) ≤35 pmol/l and no increased risk of ovarian hyperstimulation syndrome (OHSS).
What Is Known Already: The efficacy and safety of an individualized fixed daily dose of follitropin delta (based on body weight and AMH) have been established in randomized controlled trials (RCTs) using a GnRH antagonist protocol. Preliminary study data indicate that individualized follitropin delta is also efficacious in a GnRH agonist protocol (RAINBOW trial, NCT03564509).
Article Synopsis
- HPV infections are linked to anogenital cancers and warts, with the 9-valent HPV vaccine protecting against 7 high-risk types that cause 90% of cervical cancers and 90% of genital warts.
- The study aimed to compare the effectiveness of two doses of the HPV vaccine for 9 to 14-year-olds against the standard three-dose regimen for girls aged 16 to 26.
- Conducted in 15 countries, the trial involved 1,518 participants, and the main outcome focused on measuring antibody responses 1 month after vaccination to determine if the two-dose schedule was as effective as the three-dose schedule.